Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Acarbose; Glipizide; Incretins

Criteria

Inclusion Criteria:

• Newly diagnosed Type 2 Diabetes, without any previous drug treatment,

• 7.0 mmol/l <=FBG<=13.O mmol/l, HbA1C <=10%

• Body mass index (BMI) < 35kg/m2 (inclusive);

• Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted

• Having good study compliance

Exclusion Criteria:

• Intestinal surgery or recent abdominal surgery within 1 year

• Taken immunosuppressive agents, steroid,antidiarrhea agents, antibiotics and other gastrointestinal motility agents within 3 months

• Severe liver dysfunction, including serum alanine aminotransferase concentration more than 2.5 times above upper limit of normal range, abnormal renal function (GFR < 60ml/min)

• Other severe conditions which will put the patients in high risk during the study

• Any clinically significant allergic disease

• Women in pregnancy or under breast feeding